Company intelligence / Profile preview

Aresus Pharma

Munich, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

Aresus Pharma’s flagship drug, sinecatechins (Veregen®), is approved for the treatment of external genital and perianal warts. They are conducting a phase 3 study on sinecatechins ointment for actinic keratosis. No publicly reported clinical results yet for actinic keratosis, phase 3 enrolment started in September 2024.

Therapeutic areas: Infectious DiseasesDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Medigene AG (acquired rights to Veregen® from Medigene)Distribution partners transferred with the product (names not specified)

Beyond the preview

Go deeper on Aresus Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aresus Pharma.

Explore the full profile